CA3F8

BRAWN BIOTECH LTD.

November 5, 2026

BSE Limited,
Department of Corporate Services,
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort, Mumbai - 400001
Scrip Code: 530207

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Outcome of Board Meeting held on November 5, 2026

Dear Sir/Ma'am,

With reference to the captioned subject and pursuant to the provisions of Regulation 30 and Regulation 33 of SEBI Listing Regulations, this is to inform you that the Board of Directors of the Company in its meeting held today, 5th November, 2026 has considered and approved the Un-Audited Financial Results along with Limited Review Report by the Company's Statutory Auditor for the Quarter ended 30.09.2026, a Copy of which is enclosed herewith.

We wish to further inform you that the meeting of the board of directors commenced at 2:00 P.M. and concluded at 2.30 P.M.

Kindly take the same on your record and acknowledge receipt of the same.

Thanking you,
Yours faithfully,

For and on behalf of
Brawn Biotech Limited

BRAWN BIOTECH LIMITED DELHI

Sharma

Priyanka Sharma
Company Secretary & Compliance Officer
Membership No. A50385

06CC0

BRAWN BIOTECH LTD.

BRAWN BIOTECH LIMITED
CIN:L74899DL1985PLC022468
REGD. OFFICE: C-64, Lajpat Nagar-1, New Delhi 110024
Extract of Standalone Un-Audited Financial Results for the quarter and half year ended 30th September 2026

(Rs. In Lacs)

Sr. No.	Particulars	Quarter Ended			Half-yearly ended		Year Ended
		30-Sep-26	30-Jun-26	30-Sep-25	30-Sep-26	30-Sep-25	31-Mar-26
		Un-audited	Un-audited	Un-audited	Un-audited	Un-audited	Audited
1	**Revenue from operations**						
	Revenue from operations	562.45	607.88	489.10	1,170.33	1,068.87	1,697.77
	Other Income	14.11	13.85	9.12	27.96	18.21	45.40
	Total Revenue	**576.56**	**621.74**	**498.22**	**1,198.29**	**1,087.08**	**1,743.18**
2	**Expenses**						
a	Cost of material consumed	-	-	-	-	-	-
b	Purchase of stock-in-trade	449.84	223.50	536.48	673.34	927.69	1,411.44
c	Change in inventories of finished goods, work in progress and stock in trade	28.24	295.34	-120.52	323.58	-15.60	40.49
d	Employee Benefit expenses	22.20	30.55	14.55	52.75	35.07	68.36
e	Depreciation and amortisation expenses	2.98	2.99	3.10	5.97	6.17	12.20
f	Finance Cost	0.14	0.02	0.18	0.16	0.21	0.45
g	Other expenses	70.13	53.90	57.27	124.03	102.79	210.13
	Total Expenses	**573.53**	**606.30**	**491.08**	**1,179.83**	**1,056.34**	**1,743.07**
3	**Profit from Operation before Other Income, exceptional and extra-ordinary items (1-2)**	3.03	15.44	7.14	18.46	30.74	0.11
4	**Other Income**	-	-	-	-	-	-
5	**Profit from ordinary activities before exceptional items (3-4)**	3.03	15.44	7.14	18.46	30.74	0.11
6	**Exceptional Items**		-	-	-	-	-
7	**Profit from ordinary activities before tax (5-6)**	3.03	15.44	7.14	18.46	30.74	0.11
8	**Tax Expenses**	-	-		-		-93.95
9	**Profit (Loss) for the period from continuing operations (7-8)**	3.03	15.44	7.14	18.46	30.74	94.06
10	**Profit/(loss) from discontinuing operations**		-	-		-	-
11	**Tax expense of discontinuing operations**		-	-		-	-
12	**Profit/(loss) from Discontinuing operations (after tax) (10-11)**		-	-		-	-
13	**Profit (Loss) for the period (9+12)**	3.03	15.44	7.14	18.46	30.74	94.06
14	**Other Comprehensive Income**	0.70	0.09	0.35	0.79	3.55	3.65
	Total Comprehensive Income	3.73	15.53	7.49	19.26	34.30	97.71
15	Details of equity share capital	300.03	300.03	300.03	300.03	300.03	300.03
	Paid-up equity share capital						
	Face value of equity share capital						
16	Reserve excluding Revaluation Reserve						
17	Earnings per share						
i	Basic earnings per share	0.12	0.52	0.25	0.64	1.14	3.26
ii	Diluted earnings per share	0.12	0.52	0.25	0.64	1.14	3.26

NOTES :-

1 Results for the quarter and half year ended on 30th September, 2026 were reviewed by the Audit committee and then approved by the Board of Directors at their meeting held on 5th November, 2026.

2 The Statutory Auditors carried out the limited review for quarter and half year ended 30th September, 2026. The management has exercised necessary due diligence to ensure that the financial results provided a true and fair view of its affairs.

3 The above results have been prepared in accordance with the recognition and measurement principles of Ind AS 34 "Interim Financial Reporting", prescribed under Section 133 of the Companies Act, 2013 read with the Companies (Indian Accounting Standards) Rules, 2015, as amended from time to time, and other accounting principles generally accepted in India, and in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

4 The Company is engaged primarily in the business of Pharmaceuticals. Accordingly, there is no separate reportable segments as per Ind-AS 108 dealing with Operating Segments.

5 The above Standalone Un- audited Financial Results for the quarter and half year ended on 30-09-2026 are available on company's website www.brawnbiotech.com and BSE website www.bseindia.com.

6 Previous year / period figures have been regrouped / rearranged, wherever necessary to make them comparable with the current period figures.

For and on behalf of Board
For Brawn Biotech Limited

Brij Raj Gupta
Director
DIN NO. 00974969
Date: 05-11-2026
Place: Delhi

BRAWN BIOTECH LIMITED DELHI

BRAWN BIOTECH LIMITED
CIN:L74899DL1985PLC022468
REGD. OFFICE: C-64, Lajpat Nagar-1, New Delhi 110024

BRAWN BIOTECH LTD.

Rs. in Lacs

Statement of Assets and Liabilities as on 30th September 2026

Particulars	30-Sep-26 Un-Audited	31-Mar-26 Audited
ASSETS		
(1) Non-Current Assets		
Property, Plant, Equipment & Intangible Assets	30.49	36.47
Financial Assets		-
-Investment		-
- Trade Receivable	-	191.85
-Loan		-
Deferred Tax Asset (Net)	145.41	145.41
Total Non-Current Assets	175.91	373.73
(2) Current Assets		
Inventories	682.63	1,006.21
Financial Assets		-
- Trade Receivables	706.71	354.77
- Cash and cash equivalents	18.73	28.06
- Loan	0.90	1.32
- Other Financial Assets	134.67	127.77
Current Tax Assets (Net)	-	-
Other Current Assets	195.23	193.86
Total Current Assets	1,738.88	1,711.99
TOTAL ASSETS	**1,914.78**	**2,085.72**
EQUITY AND LIABILITIES		
EQUITY		
Equity Share Capital	300.03	300.03
Other Equity	153.17	133.91
TOTAL EQUITY	453.20	433.94
LIABILITIES		
(1) Non-current Liabilities		
Financial Liabilities		
- Trade Payable	-	128.97
- Other Financial Liabilities		-
Provisions	-	5.80
Deferred Tax liabilities (Net)		
Total Non-Current Liabilities	-	134.77
(2) Current Liabilities		
Financial Liabilities		
- Trade Payables	1,401.93	1,440.86
- Other Financial Liabilities	-	33.21
Other current liabilities	43.73	36.82
Provisions	15.93	6.12
Current tax liabilities	-	-
Total Current Liabilities	1,461.59	1,517.02
TOTAL EQUITY AND LIABILITIES	**1,914.78**	**2,085.72**

For and on behalf of Board
For Brawn Biotech Limited

Brij Raj Gupta
Director
DIN NO. 00974969
Place : New Delhi
Date : 05-11-2026

BRAWN BIOTECH LIMITED DELHI

0E8E7

BRAWN BIOTECH LTD.

BRAWN BIOTECH LIMITED
CIN:L74899DL1985PLC022468
REGD. OFFICE: C-64, Lajpat Nagar-1, New Delhi 110024
Cash Flow Statement for the half year ended 30th September, 2026

Rs. In Lacs.

Particulars	For the half year ended 30.09.2026		For the year ended 31.03.2026	
A. Cash flow from operating activities				
Net Profit / (Loss) before extraordinary items and tax		18.46		0.11
Adjustments for:				
Profit of sale of investment (Shares)	-		-	
Bad debts written off	-		-	
loss on sale of car	-		-	
Depreciation and amortisation	5.97		12.20	
Re-measurement losses on defined benefit plans	0.79		3.65	
Finance costs	0.16	6.92	0.45	16.29
Operating profit / (loss) before working capital changes		25.39		**16.40**
Changes in working capital:				
Adjustments for (increase) / decrease in operating assets:				
Inventories	323.58		40.49	
Trade receivables	(351.95)		(13.43)	
Long Term - Trade receivables	191.85		9.50	
Short-term loans and advances	(0.95)		19.12	
Long-term loans and advances	-		-	
Adjustments for increase / (decrease) in operating liabilities:				
Trade payables	(38.93)		617.08	
Long Term - Trade payables	(128.97)		(642.30)	
Borrowings	-		-	
Other current liabilities	6.91		(33.08)	
Other financial liabilities	(33.21)		1.82	
Current tax liabilities			-	
Short-term provisions	9.80		(2.94)	
Long-term provisions	(5.80)	(27.66)	(1.45)	(5.21)
Cash flow from extraordinary items				
Cash generated from operations		(2.28)		11.19
Net income tax (paid) / refunds & Dividend		-		
Net cash flow from / (used in) operating activities (A)		**(2.28)**		**11.19**
B. Cash flow from investing activities				
Capital expenditure on fixed assets, including capital advances	-		(2.62)	
Cash flow from extraordinary items		-		(2.62)
Net cash flow from / (used in) investing activities (B)		-		**(2.62)**
C. Cash flow from financing activities				
Proceeds from long-term borrowings				
Proceeds from other short-term borrowings	-6.90			
Finance cost	(0.16)		(0.45)	(0.45)
Cash flow from extraordinary items				
Net cash flow from / (used in) financing activities (C)		**(7.06)**		**(0.45)**
Net increase / (decrease) in Cash and cash equivalents (A+B+C)		**(9.33)**		**8.12**
Cash and cash equivalents at the beginning of the year		28.06		19.95
Effect of exchange differences on restatement of foreign currency Cash and cash equivalents				
Cash and cash equivalents at the end of the year		**18.73**		**28.06**
Reconciliation of Cash and cash equivalents with the Balance Sheet:				
Cash and cash equivalents as per Balance Sheet		18.73		28.06
Less: Bank balances not considered as Cash and cash equivalents as defined in AS 3 Cash Flow Statements (give details)				
Net Cash and cash equivalents		18.73		28.06
Add: Current investments considered as part of Cash and cash equivalents				
Cash and cash equivalents at the end of the year *		18.73		28.06
* Comprises:				
(a) Cash on hand		3.11		3.23
(b) Cheques, drafts on hand				-
(c) Balances with banks				-
(I) In current accounts		14.62		23.83
(II) Bank deposit Accounts with more than 3 months maturity		1.00		1.00

For and on behalf of Board
For Brawn Biotech Limited

Brij Raj Gupta
Director
DIN NO. 00974969
Place : New Delhi
Date : 05-11-2026

BRAWN BIOTECH LIMITED DELHI

12C1B

BRAWN BIOTECH LTD.

CFO CERTIFICATE UNDER REGULATION 33(2)(a) OF SEBI (LODR) REGULATION, 2015

To
The Board of Directors
Brawn Biotech Limited
First Floor, C-64 Lajpat Nagar-1,
Delhi, 110024.

A. I have reviewed Un-Audited Financial Results of Brawn Biotech Limited for the quarter ended 30th September 2026 and to the best of my knowledge and belief that;

a) These statements do not contain any materially untrue statement or omit any material fact or contain statements that might be misleading.

b) These statements together present a true and fair view of the listed entity's affairs and are in compliance with existing accounting standards, applicable laws and regulations.

B. There are, to the best of my knowledge and belief, no transaction entered into by the listed entity during the quarter ended 30th September 2026 which are fraudulent, illegal or violative of the listed entity's code of conduct.

C. I have indicated to the Auditors and the Audit Committee that there are no significant changes in internal control over financial reporting during the quarter and no instances of significant fraud with which they have become aware.

For Brawn Biotech Limited

Rati Garg
Chief Financial Officer

Date: 05.11.2026
Place: Delhi

CERTIFIED TRUE COPY OF THE RESOLUTION PASSED AT THE MEETING OF THE BOARD OF DIRECTORS OF BRAWN BIOTECH LIMITED ('THE COMPANY') HELD ON THURSDAY, 5TH DAY OF NOVEMBER 2026 AT ITS REGISTERED OFFICE SITUATED AT C-64, FIRST FLOOR, LAJPAT NAGAR-1, DELHI 110024, WHICH COMMENCED AT 2.00 PM AND CONCLUDED AT 2.30 PM

APPROVAL OF UNAUDITED FINANCIAL RESULTS OF THE COMPANY FOR THE QUARTER ENDED 30TH SEPTEMBER, 2026

The Chairman informed the Board that, in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR Regulations"), the Unaudited Financial Results of the Company for the quarter ended 30th September, 2026 were required to be considered and approved by the Board within forty-five days from the end of the quarter. The Chairman further informed that the Audit Committee, at its meeting held on November 5, 2026, had reviewed and recommended the said financial results to the Board for approval, along with the Limited Review Report issued by the Statutory Auditors of the Company thereon.

After Discussion & deliberation, the following resolution has been passed by the Board unanimously:

"RESOLVED THAT pursuant to Regulation 33 and other applicable regulations, if any, of the SEBI LODR Regulations, and based on the recommendation of the Audit Committee at its meeting held on November 5, 2026, the Unaudited Financial Results of the Company for the quarter ended 30th September 2026, together with the Limited Review Report dated November 5, 2026 issued thereon by Statutory Auditors of the Company, as placed before the meeting, be and are hereby considered and approved.

RESOLVED FURTHER THAT Mr. Brij Raj Gupta, Director of the Company be and is hereby authorized to sign the Un-audited financial results for the quarter ended 30th September 2026 and submit the same with stock exchange and other concerned authority."

For and on behalf of
Brawn Biotech Limited

BRAWN BIOTECH LIMITED DELHI

Priyanka Sharma
Company Secretary & Compliance Officer
Membership No. A50385

G D S M AND COMPANY
Chartered Accountants

Office No 304, 3rd floor, 17A/55, Triveni Pla
WEA, Karol bagh, Delhi-110005
Ph. 9582573375
E-mail: GAGANAGGARWAL958@GMAIL.C

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to
The Board of Directors
Brawn Biotech Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results of **Brawn Biotech Limited** ("the Company") for the quarter ended 30th September 2026 and year to date from 1st April 2026 to 30th September 2026 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

2. This Statement, which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For G D S M and Co.
Chartered Accountants
Firm Registration No. 034194N

G D S M AND COMPANY ★ FRN: 034194N ★ Chartered Accountants

Gagan Aggarwal
(Partner)
Membership No. 556973
UDIN: 26556973NGFOEC9954
Place: Delhi
Date: 05-11-2026